For many women, getting treatment for menopause symptoms has already required persistence.
Now, even after finding a treatment that works, some are facing another hurdle: actually finding it at the pharmacy.
Demand for estrogen patches has increased rapidly. According to pharmacy claims data cited in recent reporting, monthly estrogen patch prescriptions increased from approximately 594,000 in June 2024 to 1.6 million in May 2026. At the same time, multiple estradiol patch products have experienced shortages or intermittent backorders.¹˒²
The result? Some women are calling multiple pharmacies, travelling farther to fill prescriptions, receiving shorter supplies, or switching products depending on what is available.
So, why is this happening, and what does it mean for women who rely on hormone therapy?
Estrogen patches are a form of transdermal menopausal hormone therapy (MHT). Instead of taking estrogen orally, a patch applied to the skin delivers estradiol through the skin and into the bloodstream.
Menopausal hormone therapy is considered the most effective treatment for bothersome vasomotor symptoms, including hot flashes and night sweats, and can also help prevent bone loss in appropriate patients.³
Whether estrogen is used alone or alongside a progestogen depends on individual factors, including whether a person has a uterus. Hormone therapy should be individualized based on symptoms, age, medical history, personal risk factors, and treatment goals.³
Transdermal estrogen has also become an important option in menopause care because it bypasses first-pass metabolism in the liver. Research comparing oral and transdermal hormone therapy suggests the routes have different risk profiles, particularly when it comes to venous thromboembolism.⁴˒⁵
For many women, that makes patches more than simply a convenient way to take estrogen. They may be the formulation selected specifically as part of an individualized treatment plan.
One major factor is that menopause care itself is changing.
Women are talking about menopause more openly. Clinicians and patients have access to evolving evidence about hormone therapy, and conversations that were once largely absent from mainstream healthcare have become increasingly visible.
Hormone therapy recommendations have also evolved considerably since the early 2000s. Current guidance emphasizes that the benefits and risks of MHT depend on factors including age, time since menopause, formulation, dose, route of administration, duration of treatment, and whether a progestogen is used.³
In November 2025, the FDA initiated changes to remove several longstanding boxed-warning statements from menopausal hormone therapy labeling following a review of the evidence.⁶
Against that backdrop, demand for estrogen patches increased dramatically.
According to pharmacy claims data cited in reporting on the shortage, monthly prescriptions increased from approximately **594,000 in June 2024 to 1.6 million by May 2026.**¹
That’s a major shift in less than two years.
And supply hasn’t necessarily moved at the same speed.
This is where things get a little complicated.
In September 2026, the FDA acknowledged reports that patients were having difficulty readily accessing their usual estradiol transdermal patches because of increased demand. However, the agency has stated that estradiol patches remain available overall, even though availability of specific products may vary by pharmacy and location.²
The American Society of Health-System Pharmacists has also documented backorders, allocations, and intermittent availability affecting multiple estradiol transdermal products.⁷
In other words, a medication can technically remain available within the broader supply chain while individual patients still have significant difficulty finding their particular product or dose.
And when you’re the person calling pharmacy after pharmacy, that distinction may not feel very meaningful.
Transdermal patches are more complicated to manufacture than they might look.
According to the FDA, manufacturers have been increasing production, adding manufacturing shifts, expanding capacity, increasing batch sizes, and adding specialized equipment and production lines.²
But some of those changes take time.
The FDA reports that the supply of FDA-approved estradiol transdermal patches has nearly doubled over the past year, yet demand has continued to place pressure on availability.²
So this isn’t necessarily a case of manufacturers simply deciding not to make enough medication.
It’s an example of what can happen when healthcare demand grows faster than manufacturing capacity can adapt.
For someone who doesn’t rely on a prescription medication, switching from one patch to another might not sound like a big deal.
For the patient, it can be more complicated.
Research has demonstrated considerable variability in serum estradiol concentrations among women using transdermal estradiol, highlighting the importance of individualized dosing and clinical response.⁸
That doesn’t mean switching brands will automatically cause symptoms or make treatment ineffective. But it does reinforce why hormone therapy shouldn’t be treated as completely interchangeable without considering dose, formulation, response, and individual circumstances.
Shortages can also create practical burdens.
Patients may need to contact several pharmacies, refill prescriptions more frequently, or discuss alternative products with their healthcare team.
What should be a routine refill can suddenly become another healthcare task to manage.
When your usual prescription isn’t available, it can be tempting to stretch doses, cut patches, use them differently, or make another adjustment until you can find a refill.
That’s not something to do without professional guidance.
The FDA recommends contacting your pharmacist if you’re having difficulty finding your usual patch. A pharmacist may be able to locate another available FDA-approved product or determine whether substitution is appropriate. Patients can also speak with their prescribing healthcare professional about alternative estradiol products or treatment options.²
Importantly, the FDA advises patients **not to stop or change their medication without first speaking with their healthcare provider.**²
Even cutting a patch isn’t necessarily a simple workaround. Patch design varies, and altering a transdermal system may affect how medication is delivered.⁷
There’s another part of this story worth paying attention to.
For years, menopause was something many women were expected to quietly tolerate.
Now, more women are recognizing their symptoms, talking about them, and asking healthcare providers about treatment.
That’s progress.
Current evidence supports individualized use of menopausal hormone therapy, particularly for bothersome vasomotor symptoms. For healthy symptomatic women younger than 60 years or within 10 years of menopause onset who don’t have contraindications, major menopause guidance considers the benefit-risk ratio favourable for treatment of bothersome vasomotor symptoms and prevention of bone loss.³
Increased interest in menopause treatment therefore shouldn’t automatically be viewed as a problem.
The challenge is making sure healthcare infrastructure can respond when women actually seek that care.
The current estrogen patch supply pressure raises a larger question:
When demand for women’s healthcare grows, are our systems prepared to grow with it?
Stories about medication shortages can understandably make hormone therapy feel even more complicated.
But difficulty accessing one formulation doesn’t mean you should simply accept disruptive menopause symptoms or abandon a treatment that’s helping you.
It means healthcare systems need to become better prepared to support the growing number of women seeking evidence-informed menopause care.
If you can’t find your prescribed estrogen patch, speak with your pharmacist and prescribing healthcare professional about available options rather than changing your treatment independently.
And if you’re experiencing perimenopause or menopause symptoms but haven’t sought help because you’ve assumed they’re simply something you have to live with, consider starting that conversation with a qualified healthcare professional.
There are evidence-based treatment options available, and the right approach depends on your individual symptoms, health history, risks, and preferences.³
The estrogen patch access problem highlights something bigger than a medication supply issue.
Demand for menopause care has grown rapidly. The systems surrounding that care now need to catch up.
Women shouldn’t have to spend hours calling pharmacies or repeatedly worry about whether a prescribed treatment will be available when they need their next refill.
Growing awareness around menopause is progress.
Making sure women can actually access the care they’re asking for should be part of that progress too.
Photodynamic therapy is a treatment typically used in the treatment of acne, warts, and a range of cancers, including mouth (oral), head and neck, lung,
The HPV Infection: Do I Have It? But…I’ve never noticed any symptoms so I couldn’t have gotten an HPV infection? Most strains of HPV are low-risk strains that
Are you worried about HPV? Are you unclear as to what exactly HPV is? We at Papillex understand your concerns. HPV can be scary! That’s
Human beings are naturally programmed to eat foods that are healing and beneficial for our bodies. However, we all know that it isn’t always easy
Easy Delivery. Effortless Wellness.
Subscribe for:
By signing up for a Wellex subscription, you authorize use of the credit card you have on file and shipping at the frequency you have selected. Rest assured you can change or cancel at any time.
